Target

ABL1

Tyrosine-protein kinase ABL1

Also: BCR::ABL1, BCR-ABL1, BCR-ABL

20open trials
42trials in total
561publications
0researchers

Diseases

The last 24 months

New trials, publications, preprints and grants on this target, month by month.

TrialsPublicationsPreprintsGrants

Trial
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
27 Jan 2027· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL
2 Jan 2027· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
1 Dec 2026· PHASE3 · NOT_YET_RECRUITING· CTGOV
Trial
A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)
1 Dec 2026· PHASE1 · RECRUITING· CTGOV
Publication
Mechanistically distinct classes of BCR::ABL1 mutations confer resistance to asciminib.
5 Nov 2026· Blood· PUBMED
Publication
Development of an Amplicon-Based Next-Generation Sequencing Assay for Pan-type Detection of BCR::ABL1 Kinase Domain Mutations.
4 Nov 2026· Annals of laboratory medicine· PUBMED
Publication
Relcobatinib, a highly selective ATP-competitive ABL1 tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
3 Nov 2026· Leukemia· PUBMED
Publication
Longitudinal Single-Cell RNA Sequencing Reveals Evolution of Microstates and Macrostates in Chronic Myeloid Leukemia.
3 Nov 2026· Cancer research· PUBMED
Publication
Emerging BCR::ABL1 inhibitors in chronic myeloid leukemia: current advances and future directions.
2 Nov 2026· International journal of hematology· PUBMED
Publication
Peritoneal Tuberculosis and Chronic Myeloid Leukaemia: A Case of Hickam's Dictum.
1 Nov 2026· The Medical journal of Australia· PUBMED
Publication
Prospective Evaluation of Hepatitis B Virus Reactivation in Cancer Patients Receiving Tyrosine Kinase Inhibitors.
1 Nov 2026· Journal of medical virology· PUBMED
Publication
Clinical Characteristics of Coexistent Chronic Myeloid Leukemia and BCR::ABL1 Negative Myeloproliferative Neoplasms: A Retrospective Study.
1 Nov 2026· Hematological oncology· PUBMED
Publication
Correction: BCR::ABL1 tyrosine kinase inhibitors induce ribosome collisions to activate ZAK-dependent ribotoxic stress and apoptosis in chronic myeloid leukemia.
1 Nov 2026· Leukemia· PUBMED
Publication
A novel SLTM::RUNX1 acquired during CML progression and the clinical significance of concurrent BCR::ABL1 and RUNX1 rearrangements in Ph-positive leukemia.
31 Oct 2026· Cancer genetics· PUBMED
Trial
Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL
30 Oct 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTIS
Publication
ANGPT1-based targeted drug screening: Identification of Tasosartan and its activity against tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
30 Oct 2026· The Journal of international medical research· PUBMED
Publication
ELTS score and early "warning" define a 2-stage risk framework for failure-free survival in chronic-phase CML.
27 Oct 2026· Blood advances· PUBMED
Publication
Exploring the potential of vamotinib in Ph+ leukemias: is it indeed a 3rd generation tyrosine kinase-inhibitor?
26 Oct 2026· Journal of hematology & oncology· PUBMED
Publication
Programmable and selective silencing of oncogenic fusion transcripts by CRISPR-Cas13b via breakpoint sequence recognition.
16 Oct 2026· Science advances· PUBMED
Publication
Next-generation digital polymerase chain reaction assay for BCR::ABL1 in chronic myeloid leukemia: comprehensive validation for standardized measurable residual disease detection.
16 Oct 2026· Blood research· PUBMED
Publication
Targeting the eIF4F translation initiation complex disrupts BCR::ABL1 translation and overcomes drug resistance in CML.
16 Oct 2026· Leukemia· PUBMED
Publication
NGS-based retrospective profiling of BCR::ABL1 kinase domain mutations in chronic myeloid leukemia: Findings from the largest South Asian cohort.
12 Oct 2026· Leukemia research· PUBMED
Publication
Hsa_circ_0029325 drives imatinib resistance via the CDCA4/AKT axis in chronic myeloid leukemia.
10 Oct 2026· Molecular biology reports· PUBMED
Publication
Functional substitution of imatinib-inactivated canonical oncoprotein BCR::ABL1 by overexpressed PLAG1 results in BCR::ABL1-independent resistance in blast phase of chronic myeloid leukemia.
6 Oct 2026· Leukemia research· PUBMED
Publication
Significance of BCR-ABL P-loop point mutations (L248R/V) on binding to FDA approved drugs: molecular dynamics simulations and DFT studies.
6 Oct 2026· Journal of biomolecular structure & dynamics· PUBMED
Publication
Author Correction: Timing and trajectory of BCR::ABL1-driven chronic myeloid leukaemia.
1 Oct 2026· Nature· PUBMED
Publication
Profiling Tyrosine Kinase Inhibitor-Specific Signatures of Homocysteine Metabolism and Mineral Homeostasis in Chronic Myeloid Leukemia.
1 Oct 2026· Asian Pacific journal of cancer prevention : APJCP· PUBMED
Publication
De novo development of JAK2V617F-positive polycythemia vera following allogeneic hematopoietic stem cell transplantation: a report of two rare cases.
1 Oct 2026· Upsala journal of medical sciences· PUBMED
Publication
A Peripheral Blood Circular Ribonucleic Acid-Based Nomogram for Risk Stratification in Chronic Myeloid Leukemia.
1 Oct 2026· Clinical laboratory· PUBMED
Publication
Tyrosine kinase inhibitor use and risk of neurodegenerative disease: A Swedish population-based cohort study.
1 Oct 2026· Alzheimer's & dementia : the journal of the Alzheimer's Association· PUBMED

Who works on it

Researchers who published on this target. Leave out your own co-author circle to find people you do not know yet.

No published researcher profile on this target yet.

We look for a fixed list of target names in titles, keywords, intervention names and MeSH terms. A mention does not prove that the work is aimed at that target.

Report an error